OptimizeRx closed at $9.82 on Nov 4, up 5.25%, 49.5% below its 52-week closing high. Volume of 137.2K shares was 1.04× its 20-day average (close to normal).
Split-adjusted performance: +11.5% over one month, +51.8% over six months, -49.5% over one year.
In the quarter ended Jun 30, 2026, revenue was $20.50M, down 29.8% from a year earlier, with a net margin of -3.4%.
Short interest was 1.1M shares at the Oct 15 settlement, down 3.4% from the prior report (6.6% of float, 6.7 days to cover).